EAM Investors’s Apellis Pharmaceuticals APLS Stock Holding History

EAM Investors’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,407	Closed	-$2.31M	–	279
2023 Q2	$2.31M	Buy	+25,407	New	+$2.19M	0.43%	90
2022 Q4	–	Sell	-27,355	Closed	-$1.87M	–	254
2022 Q3	$1.87M	Buy	+27,355	New	+$1.62M	0.41%	102
2021 Q3	–	Sell	-35,746	Closed	-$2.26M	–	287
2021 Q2	$2.26M	Buy	+35,746	New	+$1.84M	0.35%	97
2021 Q1	–	Sell	-36,677	Closed	-$2.1M	–	335
2020 Q4	$2.1M	Buy	+36,677	New	+$1.55M	0.34%	105

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM Investors's APLS Position: Q3 2023 in Review

EAM Investors sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 25,407 shares — an estimated $2.31M sold.

EAM Investors first reported a position in APLS in Q4 2020 and held it in 4 quarters. The position peaked at $2.31M in Q2 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

EAM Investors reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
EAM Investors sold 25,407 Apellis Pharmaceuticals shares in Q3 2023, an estimated $2.31M.
EAM Investors first reported a position in Apellis Pharmaceuticals in Q4 2020 and held it in 4 quarters.
EAM Investors's Apellis Pharmaceuticals position peaked at $2.31M in Q2 2023.
256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on EAM Investors's 13F filing for Q3 2023, filed 13 Nov 2023.